½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1320987

¿ä·Î°¨¿°Áõ °Ë»ç ½ÃÀå - °Ë»ç À¯Çüº°, °Ë»ç Å°Æ® À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº° ¹× ¿¹Ãø(2023-2032³â)

Urinary Tract Infection Testing Market-By Test Type (Urinalysis, Urine Cultures, Susceptibility Testing), By Test Kit Type (Laboratory Test Kits, Home Test Kits), By Application (Urethritis, Cystitis, Pyelonephritis), By End-use & Forecast, 2023-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

2032³â±îÁö ¼¼°è ¿ä·Î°¨¿°Áõ °Ë»ç ½ÃÀå ±Ô¸ð´Â Å©°Ô È®´ëµÇ°í, ¿ìÈ£ÀûÀÎ »óȯ Á¤Ã¥, ÀÇ·á ÀÎÇÁ¶ó °³¹ßÀ» ÃËÁøÇÏ´Â Á¤ºÎ À̴ϼÅƼºê, ³ëÀÎ Àα¸ÀÇ Áõ°¡°¡ ¿ä·Î °á¼® °Ë»ç ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÕ´Ï´Ù.

¿¹¸¦ µé¾î, ¹Ì±¹ º¸°Çº¹ÁöºÎ(HHS)´Â ¿ä·Î°¨¿° ¿¹¹æ °ü¸®(UTI-PCC) À̴ϼÅƼºê¸¦ Ãâ¹ü½ÃÄ×½À´Ï´Ù. ÀÌ À̴ϼÅƼºê´Â ¿ä·Î °á¼®¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀÌ°í ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿Í È¯ÀÚ¿¡°Ô ÀÚ¿øÀ» Á¦°øÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

È¿°úÀûÀÎ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ÁÖ·Î ¿©¼º°ú ³ë³âÃþÀÇ ¿ä·Î°á¼® ¹ßº´·ü Áõ°¡·Î ÀÎÇØ ½ÃÀåÀÌ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Ä¡·áµÇÁö ¾ÊÀº ¿ä·Î°á¼®À¸·Î ÀÎÇÑ ÀáÀçÀû ÇÕº´Áõ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í, Á¶±â¿¡ Á¤È®ÇÑ °Ë»ç ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ºÐÀÚ Áø´Ü ¹× ÀÚµ¿ ¼Òº¯ ºÐ¼®±â¿Í °°Àº Áø´Ü ±â¼úÀÇ ¹ßÀüÀº Àå±âÀûÀ¸·Î ½ÃÀå ÀáÀç·ÂÀ» ³ôÀÏ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Àüü ¿ä·Î°¨¿°Áõ °Ë»ç ½ÃÀåÀº °Ë»ç À¯Çü, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ ¹× Áö¿ª¿¡ µû¶ó ºÐ·ùµË´Ï´Ù.

°Ë»ç À¯Çüº°·Î´Â ¼Òº¯ °Ë»ç ºÐ¾ß°¡ 2032³â±îÁö »ó´çÇÑ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼Òº¯ °Ë»ç´Â ¿ä·Î °á¼®À» °¨ÁöÇÏ°í Áø´ÜÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀϹÝÀûÀÌ°í ÇʼöÀûÀÎ Áø´Ü µµ±¸ÀÔ´Ï´Ù. ¼Òº¯ °Ë»ç´Â ¼Òº¯ »ùÇÃÀ» ºÐ¼®ÇÏ¿© ¹ÚÅ׸®¾Æ, ¹éÇ÷±¸ ¹× ±âŸ °¨¿° ÁöÇ¥¸¦ ½Äº°ÇÕ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¿ä·Î °á¼® ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿ä·Î °á¼®ÀÇ Áõ°¡¸¦ µÞ¹ÞħÇÏ´Â ÁÖ¿ä °Ë»ç ¹æ¹ýÀ¸·Î ¼Òº¯ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °á°úÀûÀ¸·Î ¿ä·Î °á¼® °Ë»ç ½ÃÀå¿¡¼­ ¼Òº¯ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä´Â ¿©ÀüÈ÷ ³ô½À´Ï´Ù.

¿ëµµº°·Î´Â ¿äµµ¿° ºÐ¾ß°¡ 2022-2023³â Å« ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Ä¡·áµÇÁö ¾ÊÀº ¿äµµ¿°ÀÇ ÇÕº´Áõ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ¼ºº´ ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿ä·Î °á¼® °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¿äµµ¿°À» À¯¹ßÇÏ´Â º´¿ø±ÕÀÇ Á¸À縦 È®ÀÎÇϱâ À§ÇØ ¼Òº¯¹è¾ç, ºÐÀÚÁø´Ü, ½Å¼ÓÇ׿ø°Ë»ç µî ¿ä·Î°á¼® °Ë»ç¹ýÀÌ È°¿ëµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ´õ ¸¹Àº ¼ö¿ä·Î À̾îÁö°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ¿äµµ¿° ºÐ¾ß¿¡¼­´Â äÅ÷üÀÇ Áõ°¡°¡ µµ¿òÀÌ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ÃÖÁ¾ ¿ëµµ¿¡ µû¶ó Áø´Ü ½ÇÇè½ÇÀº ¿¹Ãø ±â°£ µ¿¾È ³î¶ó¿î ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ½ÇÇè½ÇÀº ¿ä·Î°á¼®ÀÇ Á¤È®ÇÏ°í ½Ã±âÀûÀýÇÑ Áø´Ü¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, ¿ä·Î°á¼® ¿¹¹æ¿¡ µµ¿òÀÌ µË´Ï´Ù. ¿ä·Î°á¼® Á¶±â ¹ß°ßÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ¿ä·Î°á¼® »ç·Ê°¡ Áõ°¡ÇÔ¿¡ µû¶ó Áø´Ü °Ë»ç½ÇÀÇ ¿ä·Î°á¼® °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á ¼­ºñ½º Á¦°øÀÚ´Â ¼Òº¯ ¹è¾ç, ¼Òº¯ °Ë»ç ¹× ºÐÀÚ Áø´ÜÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ °Ë»ç¸¦ ¼öÇàÇϱâ À§ÇØ Áø´Ü ½ÇÇè½Ç¿¡ ÀÇÁ¸ÇÏ°í ÀÖ½À´Ï´Ù. °á°úÀûÀ¸·Î ¿ä·Î °á¼® °Ë»ç ½ÃÀåÀº ÀÌ·¯ÇÑ ½Ã¼³¿¡¼­ ¹ß»ýÇÏ´Â Áö¼ÓÀûÀÎ ¼ö¿äÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù.

Áö¿ªº°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿ä·Î°¨¿°Áõ À¯º´·ü Áõ°¡·Î ÀÎÇØ APAC ¿ä·Î°¨¿°Áõ °Ë»ç ½ÃÀåÀÌ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ÀÇ·á ÀÎÇÁ¶ó¸¦ °³¼±Çϱâ À§ÇÑ Á¤ºÎÀÇ ³ë·Â°ú ÀÇ·áºñ Áõ°¡´Â APAC ¿ä·Î°¨¿°Áõ °Ë»ç ½ÃÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç¿Í Çõ½ÅÀûÀÎ Áø´Ü ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀº ÀÌ Áö¿ªÀÇ »ê¾÷ ¼ºÀå¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¿ä·Î°¨¿°Áõ °Ë»ç ¾÷°è ÀλçÀÌÆ®

  • ¾÷°è ¼¼ºÐÈ­
  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¼¼°èÀÇ ¿ä·Î°¨¿°Áõ À¯º´·ü Áõ°¡
      • º´¿ø³» ¿ä·Î°¨¿°Áõ ¹ß»ý·ü Áõ°¡
      • ÁßÀú¼Òµæ ±¹°¡ÀÇ ³ôÀº ´ç´¢º´ À¯º´·ü
      • ¿ä·Î°¨¿°Áõ °Ë»ç Á¦Ç°¿¡ °üÇÑ ½ÅÁ¦Ç° ¹ß¸Å
    • ¾÷°èÀÇ ÀáÀçÀû À§Çè°ú °úÁ¦
      • ¿ä·Î°á¼® °Ë»ç¿¡ µû¸¥ À߸øµÈ °á°ú
      • ¾ö°ÝÇÑ ±ÔÁ¦ ü°è
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • COVID-19 ¿µÇ⠺м®
  • ±ÔÁ¦ »óȲ
    • ¹Ì±¹
    • À¯·´
  • ±â¼ú Àü¸Á
  • Porters ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï »óȲ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • °æÀï ´ë½Ãº¸µå
  • ±â¾÷ ½ÃÀå Á¡À¯À²
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« Àü¸Á ¸ÅÆ®¸¯½º

Á¦5Àå ¿ä·Î°¨¿°Áõ °Ë»ç ½ÃÀå°ú ¿¹Ãø : °Ë»ç À¯Çüº°

  • ÁÖ¿ä µ¿Çâ
  • ¼Òº¯ °Ë»ç
  • ¼Òº¯ ¹è¾ç
  • °¨¼ö¼º ½ÃÇè

Á¦6Àå ¿ä·Î°¨¿°Áõ °Ë»ç ½ÃÀå°ú ¿¹Ãø : °Ë»ç Å°Æ® À¯Çüº°

  • °Ë»ç Å°Æ® À¯Çüº° ÁÖ¿ä µ¿Çâ
  • ½ÇÇè½Ç¿ë °Ë»ç Å°Æ®
  • °¡Á¤¿ë °Ë»ç Å°Æ®

Á¦7Àå ¿ä·Î°¨¿°Áõ °Ë»ç ½ÃÀå°ú ¿¹Ãø : ¿ëµµº°

  • ÁÖ¿ä µ¿Çâ
  • ¿äµµ¿°
  • ¹æ±¤¿°
  • ½Å¿ì½Å¿°

Á¦8Àå ¿ä·Î°¨¿°Áõ °Ë»ç ½ÃÀå°ú ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • Áø´Ü ½ÇÇè½Ç
  • ÀçÅÃÀÇ·á ÇöÀå
  • ±âŸ

Á¦9Àå ¿ä·Î°¨¿°Áõ °Ë»ç ½ÃÀå°ú ¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä Áö¿ª µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • Æú¶õµå
    • ½ºÀ§½º
    • ³ë¸£¿þÀÌ
    • Çɶõµå
    • ½º¿þµ§
    • µ§¸¶Å©
    • ³×´ú¶õµå
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ´ë¸¸
    • Àεµ³×½Ã¾Æ
    • º£Æ®³²
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîƼ³ª
    • ÄÝ·Òºñ¾Æ
    • Ä¥·¹
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤

Á¦10Àå ±â¾÷ °³¿ä

  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories
  • Danaher Corporation
  • ACON Laboratories Inc.
  • Cardinal Health Inc.
  • Stryker Corporation
  • SYSMEX CORPORATION
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • LabCorp(Laboratory Corporation of America Holdings)
  • Siemens Healthineers Inc.
ksm 23.09.15

Global Urinary Tract Infection Testing Market size will expand significantly through 2032. Favorable reimbursement policies, government initiatives promoting healthcare infrastructure development, and the rising geriatric population boost the UTI testing market. For instance, the U.S. Department of Health and Human Services (HHS) launched the Urinary Tract Infection Prevention and Control (UTI-PCC) initiative. The initiative focuses on raising awareness of UTIs and providing resources to healthcare providers and patients.

The market will expand due to the increasing need for effective diagnostic solutions and the rising incidence of UTIs, primarily among women and aging people. The growing awareness about the potential complications of untreated UTIs and a need for early and accurate testing methods drives the market. Additionally, technological advancements in diagnostic techniques, such as molecular diagnostics and automated urine analyzers, will boost market potential in the long run.

The overall Urinary Tract Infection Testing Market is classified based on test type, application, end-user, and region.

Regarding the test type, the urinalysis segment will capture a modest market share by 2032. Urinalysis is a common and essential diagnostic tool used to detect and diagnose UTIs. It involves the analysis of urine samples to identify the presence of bacteria, white blood cells, and other indicators of infection. The increasing incidence of UTIs globally will push the demand for urinalysis as a primary testing method supporting its augmentation. Consequently, the demand for urinalysis in the UTI testing market remains high.

Based on the application, the urethritis segment will exhibit tremendous growth between 2022-2023. The increasing awareness about the complications of untreated urethritis and the rising incidence of sexually transmitted infections contribute to the demand for UTI testing specifically targeting urethritis. UTI testing methods, such as urine culture, molecular diagnostics, and rapid antigen tests, are utilized to identify the presence of pathogens causing urethritis, leading to more demand. Therefore, the increasing rate of adoption will support the urethritis segment.

Based on the end-use, diagnostic laboratories will rise with an admirable growth rate during the forecast period. These laboratories play a vital role in accurate and timely diagnosis of UTIs and can help prevent them. The increasing awareness about the importance of early UTI detection and the growing volume of UTI cases drive the demand for UTI testing in diagnostic laboratories. Additionally, Healthcare providers rely on diagnostic laboratories to perform various tests, including urine cultures, urinalysis, and molecular diagnostics. As a result, the UTI Testing Market benefits from the continuous demand generated by these facilities.

Regionally, APAC urinary tract infection testing market could accumulate a substantial market share due to the growing prevalence of UTIs in the Asia Pacific region. The government initiatives to improve healthcare infrastructure and the increasing healthcare expenditure further propel the UTI testing market in APAC. Moreover, the presence of major market players and the adoption of innovative diagnostic solutions contribute to industry growth in the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Methodology
  • 1.2 Market scope & definitions
  • 1.3 Base estimates and calculations
    • 1.3.1 North America
    • 1.3.2 Europe
    • 1.3.3 Asia Pacific
    • 1.3.4 Latin America
    • 1.3.5 MEA
  • 1.4 Forecast calculations
  • 1.5 Data validation
  • 1.6 COVID-19 impact analysis at global level
  • 1.7 Data sources
    • 1.7.1 Secondary
      • 1.7.1.1 Paid sources
      • 1.7.1.2 Unpaid sources
    • 1.7.2 Primary

Chapter 2 Executive Summary

  • 2.1 Urinary tract infection testing market industry 360 degree synopsis, 2018 - 2032
    • 2.1.1 Business trends
    • 2.1.2 Regional trends
    • 2.1.3 Test type trends
    • 2.1.4 Test kit type trends
    • 2.1.5 Application trends
    • 2.1.6 End-use trends

Chapter 3 Urinary Tract Infection Testing Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry ecosystem analysis
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Increasing prevalence of urinary tract infections globally
      • 3.3.1.2 Growing incidence of hospital-acquired urinary tract infection
      • 3.3.1.3 High prevalence of diabetes in low and middle-income nations
      • 3.3.1.4 Novel product launches regarding UTI testing products
    • 3.3.2 Industry pitfalls & challenges
      • 3.3.2.1 False results associated with UTI testing
      • 3.3.2.2 Stringent regulatory framework
  • 3.4 Growth potential analysis
    • 3.4.1 By test type
    • 3.4.2 By test kit type
    • 3.4.3 By application
    • 3.4.4 By end-use
  • 3.5 COVID- 19 impact analysis
  • 3.6 Regulatory landscape
    • 3.6.1 U.S.
    • 3.6.2 Europe
  • 3.7 Technology landscape
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive landscape

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2021
  • 4.3 Competitive dashboard
  • 4.4 Company market share, 2021
  • 4.5 Competitive analysis of major market players
  • 4.6 Competitive positioning matrix
  • 4.7 Strategic outlook matrix

Chapter 5 Urinary Tract Infection Testing Market and Forecast, By Test Type (USD Million)

  • 5.1 Key trends, by test type
  • 5.2 Urinalysis
  • 5.3 Urine cultures
  • 5.4 Susceptibility testing

Chapter 6 Urinary Tract Infection Testing Market and Forecast, By Test Kit Type (USD Million)

  • 6.1 Key trends, by test kit type
  • 6.2 Laboratory test kits
  • 6.3 Home test kits

Chapter 7 Urinary Tract Infection Testing Market and Forecast, By Application (USD Million)

  • 7.1 Key trends, by application
  • 7.2 Urethritis
  • 7.3 Cystitis
  • 7.4 Pyelonephritis

Chapter 8 Urinary Tract Infection Testing Market and Forecast, By End-use (USD Million)

  • 8.1 Key trends, by end-use
  • 8.2 Hospitals
  • 8.3 Diagnostic laboratories
  • 8.4 Homecare settings
  • 8.5 Others

Chapter 9 Urinary Tract Infection Testing Market and Forecast, By Region (USD Million)

  • 9.1 Key regional trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Russia
    • 9.3.7 Poland
    • 9.3.8 Switzerland
    • 9.3.9 Norway
    • 9.3.10 Finland
    • 9.3.11 Sweden
    • 9.3.12 Denmark
    • 9.3.13 The Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Taiwan
    • 9.4.7 Indonesia
    • 9.4.8 Vietnam
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Colombia
    • 9.5.5 Chile
  • 9.6 Middle East & Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Israel

Chapter 10 Company Profiles

  • 10.1 Thermo Fisher Scientific, Inc.
  • 10.2 Bio-Rad Laboratories
  • 10.3 Danaher Corporation
  • 10.4 ACON Laboratories Inc.
  • 10.5 Cardinal Health Inc.
  • 10.6 Stryker Corporation
  • 10.7 SYSMEX CORPORATION
  • 10.8 Abbott Laboratories
  • 10.9 F. Hoffmann-La Roche Ltd
  • 10.10 LabCorp(Laboratory Corporation of America Holdings)
  • 10.11 Siemens Healthineers Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦